Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, stresses the need for increased randomized controlled trials (RCTs) looking at immunotherapies for treating mesothelioma, to establish its efficacy for cost-benefit analysis. Prof. Fennell also talks about the potential of gene knockout, particularly of the BAP1 gene.
The need for RCTs in immunotherapy for mesothelioma
